The Relation of Postmenopausal Hormone Therapy to Serum Uric Acid and the Risk of Coronary Heart Disease Events: the Heart and Estrogen-progestin Replacement Study (Hers).
From: General Internal Medicine Section, Medical Service, Veterans Affairs Medical Center, and Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco 94121, USA. jasimon@itsa.ucsf.edu
Annals of epidemiology
- Publish Date: Feb 2006
- ISSN: 1047-2797
- Volume: 16
- Issue: 2
- Pages: 138-45
- Medium: Print
- Language: English
- Citation (JAMA): Simon Joel A, Lin Feng, Vittinghoff Eric, et al. The Relation of Postmenopausal Hormone Therapy to Serum Uric Acid and the Risk of Coronary Heart Disease Events: the Heart and Estrogen-progestin Replacement Study (Hers).. Feb 2006;16:138-45
Abstract
PURPOSE: To determine whether baseline serum uric acid (UA) levels and estrogen-progestin (E+P)-associated change in serum UA in postmenopausal women with coronary disease are associated with recurrent coronary heart disease (CHD) events. METHODS: 2763 postmenopausal women enrolled in the Heart and Estrogen-Progestin Replacement Study (HERS) were randomly assigned to take conjugated E+P or placebo in a secondary CHD prevention study. The primary outcome for these analyses was nonfatal myocardial infarction or CHD death during a mean follow up of 4.1 years. RESULTS: The baseline serum UA for the cohort was 5.4 mg/dl and, compared with placebo, E+P on average lowered serum UA levels slightly (0.2 mg/dl) at one year of follow up (p<0.0001). Baseline serum UA levels were associated in simple proportional hazards models with CHD events; each standard deviation increase (1.3 mg/dl) was associated with a 22% increased risk of primary CHD events (p=.0001). This association, however, was no longer statistically significant after multivariable adjustment (p=0.36). There was no association between on-study change in serum UA level and any CHD outcome. CONCLUSION: Treatment with E+P lowered serum UA levels slightly, but neither baseline UA nor change in UA affected CHD risk.
Mesh Headings (Keywords): Aged, Biological Markers, Cholesterol, HDL, Cholesterol, LDL, Coronary Disease, Creatinine, Estrogen Replacement Therapy, Estrogens, Conjugated (USP), Female, Humans, Medroxyprogesterone 17-Acetate, Postmenopause, Predictive Value of Tests, Risk Factors, Triglycerides, Uric Acid
Check for Full Text / PubMed Unique Identifier (PMID): 16039873
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.